Bivatuzumab
Bivatuzumab
Bivatuzumab (pronunciation: bi-vah-TOO-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Merck KGaA, a German multinational pharmaceutical, chemical and life sciences company.
Etymology
The name "Bivatuzumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the prefix "Bivatuz-" is unique to this specific drug.
Mechanism of Action
Bivatuzumab works by targeting the MUC1 antigen, a protein often overexpressed in cancer cells. By binding to this antigen, Bivatuzumab can help the immune system recognize and destroy cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- MUC1: A protein that is often overexpressed in cancer cells and can be targeted by certain treatments.
- Merck KGaA: The pharmaceutical company that developed Bivatuzumab.
See Also
External links
- Medical encyclopedia article on Bivatuzumab
- Wikipedia's article - Bivatuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski